CHICAGO -- December 4, 2013 -- As part of its ongoing commitment to accelerating cancer innovation and assembling tools to fight the disease, GE Healthcare, a unit of General Electric Company (NYSE: GE), will highlight the benefits of the company's broad portfolio of advanced cancer treatment solutions at the 2013 Radiological Society of North America (#RSNA13) annual meeting.
business unit
tags
Breakthrough software innovation delivers improved clinical capabilities, personalization, lower costs and operational results
CHICAGO -- December 3, 2013 -- Today at the 2013 Radiological Society of North America (RSNA) annual meeting, GE Healthcare, a unit of General Electric Company (NYSE: GE), unveiled four software breakthroughs to deliver improved clinical capabilities, productivity and diagnostic confidence for clinicians.
business unit
tags
CHICAGO -- December 2, 2013 -- GE Healthcare, a unit of General Electric Company (NYSE: GE), is dedicated to providing clinicians worldwide with leading radiation dose management innovations. X-ray dose is a critical issue and GE Healthcare has collaborated with top institutions to develop strategies to better manage it. At this year's 2013 Radiological Society of North America (#RSNA13) annual meeting, GE Healthcare is showcasing several new offerings to enable low-dose imaging procedures and help clinicians track and measure dose.
business unit
tags
Revolution CT to give clinicians a test that gives them outstanding image quality and reduced dose exposure for patients
CHICAGO -- DECEMBER 2, 2013 -- GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced at the Radiological Society of North America's 99th Scientific Assembly and Annual Meeting in Chicago, Illinois that its 510(k)-pending Revolution CT^ has captured a motion free image of the human heart in just one beat.
business unit
tags
CHALFONT ST. GILES, UK -- 19 November 2013 -- GE Healthcare Life Sciences, (NYSE: GE) and Cellectis Group (Alternext: ALCLS), the global genome engineering specialist, announced today that GE Healthcare has licenced Cellectis to develop, manufacture and sell models derived from stem cells for use in drug discovery and toxicity screening.